{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:14:02Z","timestamp":1780773242387,"version":"3.54.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/202.146\/2015"],"award-info":[{"award-number":["E-26\/202.146\/2015"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006734","name":"Instituto Nacional de Ci\u00eancia e Tecnologia de F\u00e1rmacos e Medicamentos","doi-asserted-by":"crossref","award":["465.249\/2014-0"],"award-info":[{"award-number":["465.249\/2014-0"]}],"id":[{"id":"10.13039\/501100006734","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["309229\/2018-9"],"award-info":[{"award-number":["309229\/2018-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10822-020-00327-9","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T02:02:28Z","timestamp":1593482548000},"page":"1091-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel phosphatidylinositol 4-kinases III beta (PI4KIII\u03b2) inhibitors discovered by virtual screening using free energy models"],"prefix":"10.1007","volume":"34","author":[{"given":"Natalie M.","family":"Colodette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas S.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo C.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold H.","family":"Fokoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-5038","authenticated-orcid":false,"given":"Carlos Mauricio R.","family":"Sant\u2019Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer J.","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"327_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bmcl.2018.12.001","volume":"29","author":"J Holenz","year":"2019","unstructured":"Holenz J, Stoy P (2019) Advances in lead generation. Bioorg Med Chem Lett 29:517\u2013524. https:\/\/doi.org\/10.1016\/j.bmcl.2018.12.001","journal-title":"Bioorg Med Chem Lett"},{"key":"327_CR2","volume-title":"The Practice of Medicinal Chemistry","author":"CG Wermuth","year":"2015","unstructured":"Wermuth CG, Aladous D, Raboisson P, Rognan D (2015) The Practice of Medicinal Chemistry, 4th edn. London, Elsevier","edition":"4"},{"key":"327_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ddtec.2015.01.005","volume":"14","author":"A Hersey","year":"2015","unstructured":"Hersey A, Chambers J, Bellis L et al (2015) Chemical databases: curation or integration by user-defined equivalence? Drug Discov Today Technol 14:17\u201324. https:\/\/doi.org\/10.1016\/j.ddtec.2015.01.005","journal-title":"Drug Discov Today Technol"},{"key":"327_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1021\/acs.jmedchem.8b01048","volume":"62","author":"WP Walters","year":"2019","unstructured":"Walters WP (2019) Virtual chemical libraries. J Med Chem 62:1116\u20131124. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01048","journal-title":"J Med Chem"},{"key":"327_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.drudis.2018.12.003","volume":"24","author":"M Follmann","year":"2019","unstructured":"Follmann M, Briem H, Steinmeyer A et al (2019) An approach towards enhancement of a screening library: the Next Generation Library Initiative (NGLI) at Bayer: against all odds? Drug Discov Today 24:668\u2013672. https:\/\/doi.org\/10.1016\/j.drudis.2018.12.003","journal-title":"Drug Discov Today"},{"key":"327_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/jm030267j","volume":"47","author":"M Vieth","year":"2004","unstructured":"Vieth M, Siegel MG, Higgs RE et al (2004) Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 47:224\u2013232. https:\/\/doi.org\/10.1021\/jm030267j","journal-title":"J Med Chem"},{"key":"327_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1021\/ci100023s","volume":"50","author":"K Ohno","year":"2010","unstructured":"Ohno K, Nagahara Y, Tsunoyama K, Orita M (2010) Are there differences between launched drugs, clinical candidates, and commercially available compounds? J Chem Inf Model 50:815\u2013821. https:\/\/doi.org\/10.1021\/ci100023s","journal-title":"J Chem Inf Model"},{"key":"327_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169\u2013409X(96), 00423\u20131. The article was originally published in Advanced Drug Delivery Reviews 23 (1997). Adv Drug Deliv Rev 23:3\u201326. https:\/\/doi.org\/10.1016\/S0169-409X(00)00129-0","journal-title":"Adv Drug Deliv Rev"},{"key":"327_CR9","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber DF, Johnson SR, Cheng H-Y et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615\u20132623. https:\/\/doi.org\/10.1021\/jm020017n","journal-title":"J Med Chem"},{"key":"327_CR10","doi-asserted-by":"publisher","first-page":"W623","DOI":"10.1093\/nar\/gkp456","volume":"37","author":"Y Wang","year":"2009","unstructured":"Wang Y, Xiao J, Suzek TO et al (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 37:W623\u2013W633. https:\/\/doi.org\/10.1093\/nar\/gkp456","journal-title":"Nucleic Acids Res"},{"key":"327_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin JJ, Shoichet BK (2005) ZINC: a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177\u2013182. https:\/\/doi.org\/10.1021\/ci049714+","journal-title":"J Chem Inf Model"},{"key":"327_CR12","unstructured":"Prestwick Chemical. https:\/\/www.prestwickchemical.com\/libraries-screening-lib-pcl.html. Accessed 2 Jul 2019"},{"key":"327_CR13","first-page":"239","volume-title":"Progress in medicinal chemistry","author":"A Wood","year":"2005","unstructured":"Wood A, Armour D (2005) The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. In: King FD (ed) Progress in medicinal chemistry. Elsevier, London, pp 239\u2013271"},{"key":"327_CR14","unstructured":"LASSBio Chemical Library. https:\/\/www.lassbiochemicallibrary.com. Accessed 2 Jul 2019"},{"key":"327_CR15","volume-title":"Kinase drug discovery","author":"AW Richard","year":"2011","unstructured":"Richard AW, Frederick G (2011) Kinase drug discovery, 1st edn. Royal Society of Chemistry, Cambridge","edition":"1"},{"key":"327_CR16","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1128\/JVI.02418-08","volume":"83","author":"J Borawski","year":"2009","unstructured":"Borawski J, Troke P, Puyang X et al (2009) Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol 83:10058\u201310074. https:\/\/doi.org\/10.1128\/JVI.02418-08","journal-title":"J Virol"},{"key":"327_CR17","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1038\/onc.2010.14","volume":"29","author":"J Li","year":"2010","unstructured":"Li J, Lu Y, Zhang J et al (2010) PI4KII\u03b1 is a novel regulator of tumor growth by its action on angiogenesis and HIF-1\u03b1 regulation. Oncogene 29:2550\u20132559. https:\/\/doi.org\/10.1038\/onc.2010.14","journal-title":"Oncogene"},{"key":"327_CR18","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1128\/IAI.01340-09","volume":"78","author":"AM Moorhead","year":"2010","unstructured":"Moorhead AM, Jung JY, Smirnov A et al (2010) Multiple host proteins that function in phosphatidylinositol-4-phosphate metabolism are recruited to the chlamydial inclusion. Infect Immun 78:1990\u20132007. https:\/\/doi.org\/10.1128\/IAI.01340-09","journal-title":"Infect Immun"},{"key":"327_CR19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.bcp.2012.07.034","volume":"84","author":"L Delang","year":"2012","unstructured":"Delang L, Paeshuyse J, Neyts J (2012) The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem Pharmacol 84:1400\u20131408. https:\/\/doi.org\/10.1016\/j.bcp.2012.07.034","journal-title":"Biochem Pharmacol"},{"key":"327_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12035-012-8358-6","volume":"47","author":"EL Clayton","year":"2013","unstructured":"Clayton EL, Minogue S, Waugh MG (2013) Phosphatidylinositol 4-kinases and PI4P metabolism in the nervous system: roles in psychiatric and neurological diseases. Mol Neurobiol 47:361\u2013372. https:\/\/doi.org\/10.1007\/s12035-012-8358-6","journal-title":"Mol Neurobiol"},{"key":"327_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2012.06.009","volume":"325","author":"MG Waugh","year":"2012","unstructured":"Waugh MG (2012) Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer. Cancer Lett 325:125\u2013131. https:\/\/doi.org\/10.1016\/j.canlet.2012.06.009","journal-title":"Cancer Lett"},{"key":"327_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tibs.2012.03.004","volume":"37","author":"N Altan-Bonnet","year":"2012","unstructured":"Altan-Bonnet N, Balla T (2012) Phosphatidylinositol 4-kinases: hostages harnessed to build panviral replication platforms. Trends Biochem Sci 37:293\u2013302. https:\/\/doi.org\/10.1016\/j.tibs.2012.03.004","journal-title":"Trends Biochem Sci"},{"key":"327_CR23","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1074\/jbc.M111.312561","volume":"287","author":"N Yang","year":"2012","unstructured":"Yang N, Ma P, Lang J et al (2012) Phosphatidylinositol 4-kinase III\u03b2 is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. J Biol Chem 287:8457\u20138467. https:\/\/doi.org\/10.1074\/jbc.M111.312561","journal-title":"J Biol Chem"},{"key":"327_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.yexcr.2015.03.028","volume":"337","author":"E Boura","year":"2015","unstructured":"Boura E, Nencka R (2015) Phosphatidylinositol 4-kinases: function, structure, and inhibition. Exp Cell Res 337:136\u2013145. https:\/\/doi.org\/10.1016\/j.yexcr.2015.03.028","journal-title":"Exp Cell Res"},{"key":"327_CR25","doi-asserted-by":"publisher","first-page":"12666","DOI":"10.1021\/jp1032965","volume":"114","author":"J Fanfrl\u00edk","year":"2010","unstructured":"Fanfrl\u00edk J, Bronowska AK, \u0158ez\u00e1\u010d J et al (2010) A reliable docking\/scoring scheme based on the semiempirical quantum mechanical PM6-DH2 method accurately covering dispersion and H-bonding: HIV-1 protease with 22 ligands. J Phys Chem B 114:12666\u201312678. https:\/\/doi.org\/10.1021\/jp1032965","journal-title":"J Phys Chem B"},{"key":"327_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/jm00035a013","volume":"37","author":"S Wang","year":"1994","unstructured":"Wang S, Milne GWA, Nicklaus MC et al (1994) Protein kinase C. Modeling of the binding site and prediction of binding constants. J Med Chem 37:1326\u20131338. https:\/\/doi.org\/10.1021\/jm00035a013","journal-title":"J Med Chem"},{"key":"327_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1023\/a:1022446720849","volume":"16","author":"CW Murray","year":"2002","unstructured":"Murray CW, Verdonk ML (2002) The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comput Aided Mol Des 16:741\u2013753. https:\/\/doi.org\/10.1023\/a:1022446720849","journal-title":"J Comput Aided Mol Des"},{"key":"327_CR28","volume-title":"Reviews in computational chemistry","author":"JJP Stewart","year":"1990","unstructured":"Stewart JJP (1990) Reviews in computational chemistry. Wiley, Hoboken"},{"key":"327_CR29","doi-asserted-by":"publisher","DOI":"10.5935\/1984-6835.20090007","author":"CMR SantAnna","year":"2009","unstructured":"SantAnna CMR (2009) Molecular modeling methods in the study and design of bioactive compounds: an introduction. Rev Virtual Qu\u00edmica. https:\/\/doi.org\/10.5935\/1984-6835.20090007","journal-title":"Rev Virtual Qu\u00edmica"},{"key":"327_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/156802610790232297","volume":"10","author":"L Menikarachchi","year":"2010","unstructured":"Menikarachchi L, Gascon J (2010) QM\/MM approaches in medicinal chemistry research. Curr Top Med Chem 10:46\u201354. https:\/\/doi.org\/10.2174\/156802610790232297","journal-title":"Curr Top Med Chem"},{"key":"327_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/ct600325q","volume":"3","author":"AM Wollacott","year":"2007","unstructured":"Wollacott AM, Merz KM (2007) Assessment of semiempirical quantum mechanical methods for the evaluation of protein structures. J Chem Theory Comput 3:1609\u20131619. https:\/\/doi.org\/10.1021\/ct600325q","journal-title":"J Chem Theory Comput"},{"key":"327_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cplett.2016.12.015","volume":"668","author":"R Gonz\u00e1lez","year":"2017","unstructured":"Gonz\u00e1lez R, Su\u00e1rez CF, Boh\u00f3rquez HJ et al (2017) Semi-empirical quantum evaluation of peptide: MHC class II binding. Chem Phys Lett 668:29\u201334. https:\/\/doi.org\/10.1016\/j.cplett.2016.12.015","journal-title":"Chem Phys Lett"},{"key":"327_CR33","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1021\/acs.jctc.8b00031","volume":"14","author":"I Cabeza de Vaca","year":"2018","unstructured":"Cabeza de Vaca I, Qian Y, Vilseck JZ et al (2018) Enhanced Monte Carlo methods for modeling proteins including computation of absolute free energies of binding. J Chem Theory Comput 14:3279\u20133288. https:\/\/doi.org\/10.1021\/acs.jctc.8b00031","journal-title":"J Chem Theory Comput"},{"key":"327_CR34","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1016\/j.bmc.2006.05.017","volume":"14","author":"FG Oliveira","year":"2006","unstructured":"Oliveira FG, Sant\u2019Anna CMR, Caffarena ER et al (2006) Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors. Bioorg Med Chem 14:6001\u20136011. https:\/\/doi.org\/10.1016\/j.bmc.2006.05.017","journal-title":"Bioorg Med Chem"},{"key":"327_CR35","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1128\/AAC.00946-12","volume":"56","author":"MJ LaMarche","year":"2012","unstructured":"LaMarche MJ, Borawski J, Bose A et al (2012) Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob Agents Chemother 56:5149\u20135156. https:\/\/doi.org\/10.1128\/AAC.00946-12","journal-title":"Antimicrob Agents Chemother"},{"key":"327_CR36","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1039\/C3CC48391F","volume":"50","author":"MJ Waring","year":"2014","unstructured":"Waring MJ, Andrews DM, Faulder PF et al (2014) Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase \u03b1- but not \u03b2-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation. Chem Commun 50:5388\u20135390. https:\/\/doi.org\/10.1039\/C3CC48391F","journal-title":"Chem Commun"},{"key":"327_CR37","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1021\/acs.jmedchem.5b00499","volume":"58","author":"I Mejdrov\u00e1","year":"2015","unstructured":"Mejdrov\u00e1 I, Chalupsk\u00e1 D, K\u00f6gler M et al (2015) Highly selective phosphatidylinositol 4-kinase III\u03b2 inhibitors and structural insight into their mode of action. J Med Chem 58:3767\u20133793. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00499","journal-title":"J Med Chem"},{"key":"327_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/acs.jmedchem.6b01465","volume":"60","author":"I Mejdrov\u00e1","year":"2017","unstructured":"Mejdrov\u00e1 I, Chalupsk\u00e1 D, Pla\u010dkov\u00e1 P et al (2017) Rational design of novel highly potent and selective phosphatidylinositol 4-kinase III\u03b2 (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology. J Med Chem 60:100\u2013118. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01465","journal-title":"J Med Chem"},{"key":"327_CR39","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/acs.jmedchem.5b01311","volume":"59","author":"FU Rutaganira","year":"2016","unstructured":"Rutaganira FU, Fowler ML, McPhail JA et al (2016) Design and structural characterization of potent and selective inhibitors of phosphatidylinositol 4 kinase III\u03b2. J Med Chem 59:1830\u20131839. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01311","journal-title":"J Med Chem"},{"key":"327_CR40","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1016\/j.bmcl.2016.04.002","volume":"26","author":"M \u0160\u00e1la","year":"2016","unstructured":"\u0160\u00e1la M, K\u00f6gler M, Pla\u010dkov\u00e1 P et al (2016) Purine analogs as phosphatidylinositol 4-kinase III\u03b2 inhibitors. Bioorg Med Chem Lett 26:2706\u20132712. https:\/\/doi.org\/10.1016\/j.bmcl.2016.04.002","journal-title":"Bioorg Med Chem Lett"},{"key":"327_CR41","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","volume":"17","author":"TA Halgren","year":"1996","unstructured":"Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17:490\u2013519","journal-title":"J Comput Chem"},{"key":"327_CR42","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00894-007-0233-4","volume":"13","author":"JJP Stewart","year":"2007","unstructured":"Stewart JJP (2007) Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements. J Mol Model 13:1173\u20131213. https:\/\/doi.org\/10.1007\/s00894-007-0233-4","journal-title":"J Mol Model"},{"key":"327_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM (2000) The protein data bank. Nucleic Acids Res 28:235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235","journal-title":"Nucleic Acids Res"},{"key":"327_CR44","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1126\/science.1253397","volume":"344","author":"JE Burke","year":"2014","unstructured":"Burke JE, Inglis AJ, Perisic O et al (2014) Structures of PI4KIII complexes show simultaneous recruitment of Rab11 and its effectors. Science 344:1035\u20131038. https:\/\/doi.org\/10.1126\/science.1253397","journal-title":"Science"},{"key":"327_CR45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/ci800298z","volume":"49","author":"O Korb","year":"2009","unstructured":"Korb O, St\u00fctzle T, Exner TE (2009) Empirical scoring functions for advanced protein\u2212ligand docking with PLANTS. J Chem Inf Model 49:84\u201396. https:\/\/doi.org\/10.1021\/ci800298z","journal-title":"J Chem Inf Model"},{"key":"327_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00894-012-1667-x","volume":"19","author":"JJP Stewart","year":"2013","unstructured":"Stewart JJP (2013) Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters. J Mol Model 19:1\u201332. https:\/\/doi.org\/10.1007\/s00894-012-1667-x","journal-title":"J Mol Model"},{"key":"327_CR47","doi-asserted-by":"publisher","first-page":"16385","DOI":"10.1021\/jp9610776","volume":"100","author":"CC Chambers","year":"1996","unstructured":"Chambers CC, Hawkins GD, Cramer CJ, Truhlar DG (1996) Model for aqueous solvation based on class IV atomic charges and first solvation shell effects. J Phys Chem 100:16385\u201316398. https:\/\/doi.org\/10.1021\/jp9610776","journal-title":"J Phys Chem"},{"key":"327_CR48","doi-asserted-by":"publisher","first-page":"W441","DOI":"10.1093\/nar\/gkp253","volume":"37","author":"RZ Cer","year":"2009","unstructured":"Cer RZ, Mudunuri U, Stephens R, Lebeda FJ (2009) IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res 37:W441\u2013W445. https:\/\/doi.org\/10.1093\/nar\/gkp253","journal-title":"Nucleic Acids Res"},{"key":"327_CR49","unstructured":"Nunes IKC (2013) Novos inibidores de fosfodiesterases 4 an\u00e1logos de LASSBio-488 \u2013 desenho, s\u00edntese e an\u00e1lise comparativa de suas propriedades f\u00edsico-qu\u00edmicas e cin\u00e9ticas. PhD Thesis, Universidade Federal do Rio de Janeiro"},{"key":"327_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/0929867053363540","volume":"12","author":"L Lima","year":"2005","unstructured":"Lima L, Barreiro E (2005) Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 12:23\u201349. https:\/\/doi.org\/10.2174\/0929867053363540","journal-title":"Curr Med Chem"},{"key":"327_CR51","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/B978-0-12-409547-2.12290-5","volume-title":"Comprehensive medicinal chemistry III","author":"LM Lima","year":"2017","unstructured":"Lima LM, Barreiro EJ (2017) Beyond bioisosterism: new concepts in drug discovery. Comprehensive medicinal chemistry III. Elsevier, New York, pp 186\u2013210"},{"key":"327_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev.biophys.36.040306.132550","volume":"36","author":"MK Gilson","year":"2007","unstructured":"Gilson MK, Zhou H-X (2007) Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 36:21\u201342. https:\/\/doi.org\/10.1146\/annurev.biophys.36.040306.132550","journal-title":"Annu Rev Biophys Biomol Struct"},{"key":"327_CR53","doi-asserted-by":"publisher","first-page":"16968","DOI":"10.1021\/ja406995j","volume":"135","author":"P Kukic","year":"2013","unstructured":"Kukic P, Farrell D, McIntosh LP et al (2013) Protein dielectric constants determined from NMR chemical shift perturbations. J Am Chem Soc 135:16968\u201316976. https:\/\/doi.org\/10.1021\/ja406995j","journal-title":"J Am Chem Soc"},{"key":"327_CR54","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/nprot.2007.361","volume":"2","author":"ZA Knight","year":"2007","unstructured":"Knight ZA, Feldman ME, Balla A et al (2007) A membrane capture assay for lipid kinase activity. Nat Protoc 2:2459\u20132466. https:\/\/doi.org\/10.1038\/nprot.2007.361","journal-title":"Nat Protoc"},{"key":"327_CR55","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1016\/j.bmcl.2014.07.015","volume":"24","author":"EP Keaney","year":"2014","unstructured":"Keaney EP, Connolly M, Dobler M et al (2014) 2-Alkyloxazoles as potent and selective PI4KIII\u03b2 inhibitors demonstrating inhibition of HCV replication. Bioorg Med Chem Lett 24:3714\u20133718. https:\/\/doi.org\/10.1016\/j.bmcl.2014.07.015","journal-title":"Bioorg Med Chem Lett"},{"key":"327_CR56","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejmech.2007.03.032","volume":"43","author":"LM Lima","year":"2008","unstructured":"Lima LM, Frattani FS, dos Santos JL et al (2008) Synthesis and anti-platelet activity of novel arylsulfonate\u2013acylhydrazone derivatives, designed as antithrombotic candidates. Eur J Med Chem 43:348\u2013356. https:\/\/doi.org\/10.1016\/j.ejmech.2007.03.032","journal-title":"Eur J Med Chem"},{"key":"327_CR57","unstructured":"Silva TF (2012) Planejamento, s\u00edntese e avalia\u00e7\u00e3o farmacol\u00f3gica de uma nova s\u00e9rie de derivados cicloalquil-N-Acilidrazonas an\u00e1logos de LASSBio-294. MSc. Dissertation, Universidade Federal do Rio de Janeiro"},{"key":"327_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2013.10.058","volume":"71","author":"MLDC Barbosa","year":"2014","unstructured":"Barbosa MLDC, Lima LM, Tesch R et al (2014) Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. Eur J Med Chem 71:1\u201314. https:\/\/doi.org\/10.1016\/j.ejmech.2013.10.058","journal-title":"Eur J Med Chem"},{"key":"327_CR59","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1016\/j.bmcl.2018.07.015","volume":"28","author":"S Thota","year":"2018","unstructured":"Thota S, Rodrigues DA, de Pinheiro P et al (2018) N-Acylhydrazones as drugs. Bioorg Med Chem Lett 28:2797\u20132806. https:\/\/doi.org\/10.1016\/j.bmcl.2018.07.015","journal-title":"Bioorg Med Chem Lett"},{"key":"327_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cbpa.2010.03.020","volume":"14","author":"N Thorne","year":"2010","unstructured":"Thorne N, Auld DS, Inglese J (2010) Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr Opin Chem Biol 14:315\u2013324. https:\/\/doi.org\/10.1016\/j.cbpa.2010.03.020","journal-title":"Curr Opin Chem Biol"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-020-00327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-020-00327-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-020-00327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:26:06Z","timestamp":1744176366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-020-00327-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1007\/s10822-020-00327-9","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}